​​ Molnupiravir for Early, Outpatient Treatment of Covid-19 | UPDATES IN MEDICINE

​​ Molnupiravir for Early, Outpatient Treatment of Covid-19

Oral outpatient treatment for Covid-19 is needed. In this phase 3, double-blind, randomized, controlled trial, molnupiravir, a small-molecule antiviral, was studied in unvaccinated patients with less than 5 days of Covid-19 illness. By day 29, hospitalization for progression of Covid-19 was lower with molnupiravir (6.8%) than with placebo (9.7%).


@Updates_in_Medicine